The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, Georgina S Humphreys, Tesfay Abreha, Sisay G Alemu, Arletta Anez, Nicholas M Anstey, Ghulam R Awab, J Kevin Baird, Bridget E Barber, Isabelle Borghini-Fuhrer, Cindy S Chu, Umberto D'Alessandro, Prabin Dahal, Andre Daher, Peter J de Vries, Annette Erhart, Margarete SM Gomes, Lilia Gonzalez-Ceron Show all
Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2018
BACKGROUND: Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure. We did a systematic review and meta-analysis to investigate the effect of chloroquine dose and the addition of primaquine on the risk of recurrent vivax malaria across different settings. METHODS: A systematic review done in MEDLINE, Web of Science, Embase, and Cochrane Database of Systematic Reviews identified P vivax clinical trials published between Jan 1, 2000, and March 22, 2017. Principal investigators were invited to share individual patient data, which were pooled using standardised methods. Cox regression analyses with random effects for study site ..View full abstract
Related Projects (1)
Wellcome Trust, Australian National Health and Medical Research Council, and Bill & Melinda Gates Foundation.